Read more
With Cholesterol, Drs. Anna Bukiya and Alex Dopico have compiled a comprehensive resource on biological and clinical aspects of cholesterol, spanning biophysics and biochemistry, as well as the latest pharmacological discoveries employed to tackle disorders associated with abnormal cholesterol levels. Early chapters on basic biology offer guidance in cholesterol lab chemistry, cholesterol metabolism and synthesis, molecular evolution of cholesterol and sterols, cholesterol peptides, and cholesterol modulation. Chapters on cellular and organismal development discuss cholesterol transport in blood, lipoproteins, and cholesterol metabolism; cholesterol detection in the blood; cellular cholesterol levels; hypercholesterolemia; and the role of cholesterol in early human development. Pathophysical specialists consider familial hypobetalipoproteinemia, critical illness and cholesterol levels, coronary artery disease, CESD, cholesterol and viral pathology, cholesterol and neurodegenerative disorders, and cholesterol and substance use disorders. A final section examines pharmacology of drug delivery systems targeting cholesterol related disorders, cholesterol receptors, cholesterol reduction, statins, citrate lyase, cyclodextrins, and clinical management.
Cholesterol: From Biophysics and Biochemistry to Pathology and Pharmacology empowers researchers, students, and clinicians across various disciplines to advance new cholesterol-based studies, improve clinical management, and drive drug discovery.
About the author
Dr. Anna Bukiya’s PhD laboratory focuses on lipid modulation of ion channel function in excitable tissues and sensitivity to drugs. Dr. Bukiya’s work has been consistently funded by the NIH and private foundations, and she has published 43 original research articles, authored or co-authored 10 reviews, and 9 book chapters. Dr. Bukiya also co-edited two books and served as a sole editor on one book, all focused on the role of lipids in modulating protein function during normal physiology and pathological conditions. The Bukiya laboratory utilizes computational modelling of cholesterol-protein interactions, biochemical and fluorescence microscopy-based quantification of cellular cholesterol levels, rat models of high-cholesterol diet, and statin use to control cholesterol levels in vivo. Dr. Bukiya is a current member of several societies, including Biophysical Society, International Drug Abuse Research Society, and American Society for Pharmacology and Experimental Therapeutics.Dr. Alex Dopico MD, PhD received his M.D. from the University of Buenos Aires, specializing in arterial hypertension. Following his Ph.D. in Pharmacology, he conducted postdoctoral training at UMass Worcester focusing on the regulation of ion channels by lipids and alcohols. Over two decades, the Dopico laboratory has addressed ion channel regulation by a wide variety of lipids, including fatty acids, leukotrienes, glycerophospholipids, PIP2 and related phosphoinositides, bile acids and other cholanes, pregnenolone and cholesterol itself. His studies on alcohol and toluene aim at determining the relative contribution of ion channels and their surrounding membrane lipids to drug action, addressing the impact of drug action on organ function, with a focus on cerebral arteries. In 2009, he received a Merit Award from NIAAA for his work on ethanol actions on slo1 channels. He is member of the National Advisory Committee on Alcohol Abuse & Alcoholism.
